EPS for Alimera Sciences, Inc. (ALIM) Expected At $-0.04

April 23, 2018 - By Henry Gaston

Alimera Sciences, Inc. (NASDAQ:ALIM) LogoInvestors sentiment decreased to 1 in Q4 2017. Its down 0.64, from 1.64 in 2017Q3. It dropped, as 4 investors sold Alimera Sciences, Inc. shares while 8 reduced holdings. 3 funds opened positions while 9 raised stakes. 28.68 million shares or 0.99% more from 28.40 million shares in 2017Q3 were reported.
Millennium Management Ltd Company has invested 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Comml Bank Of Montreal Can reported 500 shares. 10,000 are owned by Shufro Rose And Co Ltd. Valley National Advisers reported 400 shares or 0% of all its holdings. Susquehanna Limited Liability Partnership holds 0% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM) for 26,098 shares. Barclays Public Lc holds 93 shares. Acuta Partners Llc has 0.24% invested in Alimera Sciences, Inc. (NASDAQ:ALIM). Knott David M invested 0.11% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM). Geode Lc, Massachusetts-based fund reported 144,795 shares. Pnc Grp reported 196,300 shares. 28,315 were accumulated by Bancshares Of Ny Mellon Corp. Weiss Multi holds 0% or 80,000 shares. Moreover, Morgan Stanley has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM) for 400 shares. Strs Ohio has 43,569 shares for 0% of their portfolio. Northern Trust has invested 0% in Alimera Sciences, Inc. (NASDAQ:ALIM).

Since January 16, 2018, it had 1 buy, and 10 sales for $290,803 activity. Myers C. Daniel sold $63,379 worth of stock or 52,900 shares. EISWIRTH RICHARD S JR had sold 14,494 shares worth $17,890 on Tuesday, January 16. Another trade for 25,500 shares valued at $31,475 was sold by Holland David. 20,000 shares valued at $22,800 were bought by ARMISTICE CAPITAL – LLC on Friday, February 2. The insider Green Kenneth sold 10,638 shares worth $12,742.

Analysts expect Alimera Sciences, Inc. (NASDAQ:ALIM) to report $-0.04 EPS on May, 14.They anticipate $0.06 EPS change or 60.00 % from last quarter’s $-0.1 EPS. After having $-0.10 EPS previously, Alimera Sciences, Inc.’s analysts see -60.00 % EPS growth. It closed at $1.12 lastly. It is down 28.28% since April 23, 2017 and is downtrending. It has underperformed by 39.83% the S&P500.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company has market cap of $78.38 million. It focuses on diseases affecting the back of the eye or retina. It currently has negative earnings. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Alimera Sciences, Inc. (NASDAQ:ALIM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: